Comparison of proteolytic, cytotoxic and anticoagulant properties of chromatographically fractionated bromelain to un-fractionated bromelain.
Bromelain
cancer
coagulation
cytotoxic
proteolysis
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
10
2020
accepted:
02
03
2021
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Bromelain consisting of a number of proteolytic enzymes possess anticancer and thrombotic properties. Hence, four chromatically separated fractions were examined for their proteolytic, anticancer and antithrombotic activity. Bromelain fractions were separated using ion-exchange column chromatography. Proteolytic properties were assessed using standard azocasein assay. Anticancer properties were first assessed using four different cell lines PANC-1, HEP 2B, HEP 3G and OVCAR-3 on cells grown in 96 well plates. Subsequently, fraction 2 and fraction 3 combined with gemcitabine were tested in ASPC-1 cells. Then cytotoxicity of fraction 3 was compared to bromelain in combination with doxorubicin and N-acetylcysteine on HEP G2 and HEP 3B cells. Finally, the anticoagulation effect of fraction 3 or bromelain combined with N-acetylcysteine was evaluated using human blood. Fraction 3 showed the highest proteolytic activity (5% greater than standard bromelain) whilst others were less active. Cytotoxicity as assessed by IC50 indicated fraction 3 to be the most potent whilst the others did not follow their proteolytic potency order. OVCAR-3 was the most sensitive amongst the cell lines. Fraction 3 showed higher potency in combination with gemcitabine in ASPC-1 cells compared to fraction 2. Similarly, fraction 3 in combination with doxorubicin showed higher toxicity when compared to bromelain. Fraction 3 or bromelain only showed thrombolytic activity in combination with N-acetylcysteine. Fraction 3 may be developed for clinical use since it showed better cytotoxicity compared to bromelain.
Types de publication
Journal Article
Langues
eng
Pagination
4309-4321Informations de copyright
AJTR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Cardiovasc Diabetol. 2011 May 21;10:43
pubmed: 21600014
Nat Rev Cancer. 2009 Dec;9(12):874-85
pubmed: 19935676
J Biol Chem. 1960 Jan;235:99-107
pubmed: 14425299
Biotechnol Res Int. 2012;2012:976203
pubmed: 23304525
Int J Cancer. 1997 Jul 3;72(1):87-94
pubmed: 9212228
Sci Rep. 2018 Jul 31;8(1):11508
pubmed: 30065388
Front Immunol. 2015 May 06;6:215
pubmed: 25999953
Eur J Surg Oncol. 2021 Jan;47(1):115-122
pubmed: 31679953
Planta Med. 1990 Jun;56(3):249-53
pubmed: 2203073
Med Hypotheses. 1980 Nov;6(11):1123-33
pubmed: 6256612
J Burn Care Res. 2010 Sep-Oct;31(5):795-802
pubmed: 20661148
Pleura Peritoneum. 2017 Jun 1;2(2):111-117
pubmed: 30911639
Cancer Lett. 2010 Apr 28;290(2):148-56
pubmed: 19700238
Blood Coagul Fibrinolysis. 2016 Oct;27(7):745-752
pubmed: 25517253
Anticancer Drugs. 2014 Feb;25(2):150-60
pubmed: 24366282
Circulation. 2010 Mar 2;121(8):1033-44
pubmed: 20194876
Int J Cancer. 2014 Jan 15;134(2):478-86
pubmed: 23843173
Cytotechnology. 2015 Jan;67(1):1-12
pubmed: 25002206
Am J Transl Res. 2020 Nov 15;12(11):7404-7419
pubmed: 33312377
BMC Cancer. 2014 Apr 01;14:234
pubmed: 24690311
Biochim Biophys Acta. 2014 Aug;1846(1):13-25
pubmed: 24709009
Onco Targets Ther. 2013 Apr 16;6:403-9
pubmed: 23620673
Biomed Res Int. 2016;2016:8409183
pubmed: 26925415
Circulation. 2017 Aug 15;136(7):646-660
pubmed: 28487393
J Ethnopharmacol. 1988 Feb-Mar;22(2):191-203
pubmed: 3287010
Cancer Invest. 2013 May;31(4):241-50
pubmed: 23570457
Phytochemistry. 2017 Jun;138:29-51
pubmed: 28238440
Expert Rev Mol Med. 2012 Feb 03;14:e4
pubmed: 22306029
Nat Protoc. 2006;1(3):1112-6
pubmed: 17406391
Cell Mol Life Sci. 2001 Aug;58(9):1234-45
pubmed: 11577981